Correlative Biomarker Study in Patients With Myeloproliferative Disorders

Completed

Conditions studied: Myeloproliferative Disease, Myelofibrosis, Idiopathic Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera

In brief

Researchers will use abnormal blood and/or bone marrow cells, or materials derived from these abnormal cells, like DNA, RNA, protein or plasma, in laboratory studies. Toenail clippings will provide normal material like DNA for comparison with the abnormal material derived from the blood and/or bone marrow. The results of these studies will be correlated with subjects' disease symptoms and response to their experimental treatment. The MPD-RC researchers are interested in studying molecules from the blood and bone marrow, the exact molecules changing over time with the investigators choosing only the most promising for investigation. The investigators are attempting to better understand the causes of MPD and to develop improved methods for the diagnosis and treatment of these diseases. These syndromes carry a high risk of developing leukemia. It is important to continue to learn more about these blood cancers and to learn more about the effectiveness and potential side effects of various treatments. It is believed that further basic knowledge about these cancer cells as well as the effects of treatment will lead to the improvement of current therapies and the development of entirely new treatments for these diseases. The MPD-RC is hoping to determine if a number of laboratory tests (biomarkers) will allow for the prediction of response in future patients to the treatment they would receive.

Key facts

Study ID

NCT00665067

Run by

Icahn School of Medicine at Mount Sinai

People needed

592

Starts

2007-04-01

Expected to finish

2018-07-20

Last updated by the study team

2018-12-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients are to be registered to this study if they meet the eligibility criteria for one of the MPD-RC treatment protocols linked to this study.
• Patients diagnosed with the following Myeloproliferative disorders including: polycythemia vera (PV), idiopathic myelofibrosis (IM), and essential thrombocythemia (ET) who are participating in treatment protocols of the MPD-RC are eligible.
• Patients must have signed an informed consent to participate in a Myeloproliferative Disorders Research Consortium (MPD-RC) treatment study to which this protocol is a companion study. The subject must also have signed a consent to participate in this mandatory companion study.

You may not qualify if…

• See inclusion criteria.

Where it is running

• Mayo Clinic — Scottsdale, Arizona, United States
• The Palo Alto Clinic — Palo Alto, California, United States
• Georgetown University — Washington D.C., District of Columbia, United States
• Emory Hospital — Atlanta, Georgia, United States
• University of Illinois at Chicago — Chicago, Illinois, United States
• University of Maryland — Baltimore, Maryland, United States
• Icahn School of Medicine at Mount Sinai — New York, New York, United States
• Weill Cornell Medical College — New York, New York, United States
• New York Blood Center — New York, New York, United States
• Duke University Medical Center — Durham, North Carolina, United States
• Wake Forest University Baptist Medical Center — Winston-Salem, North Carolina, United States
• Ohio State University — Columbus, Ohio, United States
• Geisinger Cancer Center — Hazleton, Pennsylvania, United States
• University of Pennsylvania — Philadelphia, Pennsylvania, United States
• University of Utah — Salt Lake City, Utah, United States
• Princess Margaret Cancer Centre — Toronto, Ontario, Canada
• Ospedali Riuniti di Bergamo — Bergamo, Italy
• University of Florence — Florence, Italy
• Ospedale San Martino Genova — Genova, Italy
• San Matteo Hospital — Pavia, Italy
• Universita Cattolica del Sacro Cuore — Rome, Italy
• Guy's and St Thomas' NHS Foundation Trust — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.